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Abstract
Objective: Demonstrate the safety and effectiveness of palatal foreshortening and
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Head and Neck Surgery, Advocate Illinois
Masonic Medical Center, Chicago, Illinois

stiffening in reducing snoring severity in nonobstructive sleep apnea (non-OSA)
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patients complaining of chronic disruptive snoring.
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Methods: In a US-based 8-center, open-label, prospective, single-arm cohort study,
52 consenting adults with chronic disruptive snoring (snoring impacting a patient's life
and causing patient or bed partner to seek medical intervention) were treated via officebased placement of resorbable, bidirectional, barbed suture implants into the soft palate
under local anesthesia. Prior to intervention, home sleep tests (HSTs) were performed to
rule out OSA and to document snoring noise level. Both subject and their bed/sleep
partners (also consented) completed questionnaires including: bed/sleep partner's
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scored visual analog scale (VAS) for subjects' snoring severity, and subject scoring for
Epworth Sleepiness Scale (ESS) and Pittsburgh Sleep Quality Index (PSQI). Following
intervention, HSTs, VAS, ESS and PSQI were repeated at 30, 90 and 180 days.
Results: Mean baseline bed/sleep partner VAS was 7.81 ± 1.59. Mean postimplant
VAS scores decreased significantly at each measured interval; to 5.77±2.35 (P < .001)
at 30 days, 4.48 ± 1.81 (P < .001) at 90 days, and 5.40 ± 2.28 (P < .001) at 180 days.
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Post treatment improvements in daytime sleepiness and QOL were also observed.
Two partial extrusions were reported. No further adverse events were identified.
Conclusion: The current study demonstrates the safety and efficacy of the Elevoplasty
procedure in reducing snoring severity over a follow-up period of 6 months.
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INTRODUCTION

Chronic and disruptive snoring is a common sleeping disorder affecting more than 37 million people in the United States.1 Snoring is more
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frequent in adults, males, in the overweight and usually worsens with
age. Often, snoring is glossed over as an entity and attention diverts

TABLE 1

Primary endpoint

to its relationship to obstructive sleep apnea (OSA). However, snoring

Change between baseline and 30-day bed/sleep partner snoring
severity VAS

can have significant bothersome, if not serious consequences to the
individual and to others sharing a common sleeping space. Snoring

Secondary endpoints

disrupts sleep and may lead to excessive daytime sleepiness and

1. Change between baseline and 90-day bed/sleep partner snoring
severity VAS

decreases in performance and productivity, lack of concentration, irritability, and decreased libido.2-5 Night-time snoring almost certainly

2. Change between baseline and 30-day HST snoring noise ratio
measure #1

disrupts the sleep of those in close proximity, leading to similar consequences of sleep deprivation, as well as the associated social discord

3. Change between baseline and 30-day HST snoring noise ratio
measure #2

6-9

and even estrangement.

4. Change between baseline and 90-day HST snoring noise ratio
measure #1

Whether primary or related to OSA, snoring is the result of vibration of oro- and/or nasopharynx tissue caused by turbulent airflow

5. Change between baseline and 90-day HST snoring noise ratio
measure #2

through the relaxed airway during sleep. Thus, virtually all current
treatments involve methods to open the airway. Life-style modifica-

6. Change between baseline and 30-day Pittsburgh Sleep Quality
Index (PSQI) Score

tions include weight loss, smoking cessation, limiting alcohol consumption, and improved sleep hygiene.

10-12

The S.I.Le.N.C.E. prospectively-defined study endpoints

Over-the-counter treatment

7. Change between baseline and 30-day Epworth Sleepiness Scale
(ESS)

options include nasal sprays, nasal strips or dilators, lubricating sprays,
and “anti-snore” clothing and pillows. Surgical correction is usually

8. Change between baseline and 90-day PSQI score

reserved for patients with associated moderate to severe OSA. Non-

9. Change between baseline and 90-day ESS

surgical snoring treatment often focuses on palate stiffening. Methods

10. Change between baseline and 180-day bed/sleep partner
snoring VAS

include injection sclerotherapy, laser therapy, cautery procedures,
radiofrequency ablation and palatal implants.13-19 These procedures

11. Change between baseline and 180-day PSQI score

usually result in palatal stiffening without significant palatal shortening

12. Change between baseline and 180-day ESS

and all have met limited success in selected patients. To improve suc-

13. Change between baseline and 180-day HST snoring noise ratio
measure #1

cess rate and reduce morbidity, an office-based procedure that would
both stiffen and foreshorten the palate was tested. The Elevoplasty

14. Change between baseline and 180-day HST snoring noise ratio
measure #2

procedure demonstrated effectiveness and safety in a single-center
pilot study employing a prototype device.20 Based on these results a
multicenter, prospective study was designed for the United States.

Abbreviations: HST, home sleep test; VAS, visual analog scale.

The objective of the Snoring Intervention via Elevoplasty in a Nonsurgical Clinical Environment (S.I.Le.N.C.E.) trial was to evaluate the

efficacy endpoint was the mean within-subject change of snoring

safety and effectiveness of a minimally invasive implant of fully

visual analog scale (VAS) from baseline (prior to implant) to Day

resorbable, bidirectional barbed sutures into the soft palate for the

30 postimplant as completed by the study subject's bed/sleep partner.

treatment of chronic, disruptive, primary snoring using the Elevo kit

There were multiple secondary endpoints as noted in Table 1 ranked

(Zelegent, Inc, Irvine, California) and the Elevoplasty procedure.

in order of relevance to the study.

2

2.2

2.1

MATERIALS AND METHODS

|
|

Study design and outcome measures

|

Selection or screening

Prospective subjects presented to the study centers with complaints
of chronic, disruptive snoring and negative screening for OSA. Sub-

This prospective, multicenter, single-arm study was initiated at eight

jects deemed qualified to participate were informed about the trial,

sites in the United States (ClinicalTrials.gov ID: NCT03083106). It was

the proposed implant procedure and follow-up requirements and pro-

designed to evaluate the technical safety and effectiveness of the Elevo

vided with IRB-approved reading material and copies of the informed

minimally invasive, barbed, absorbable suture implant in the reduction

consent forms for both subject and bed/sleep partner. Identified

of simple snoring through subjective evaluation of snoring and objective

prospective subjects (and their bed/sleep partners) were invited to a

snoring sound analysis. The protocol and potential sites and investiga-

baseline visit where full informed consent was provided and informed

tors were reviewed and approved by the Western Institutional Review

consent forms were signed, and inclusion/exclusion criteria (Table 2)

Board (WIRB, Puyallup, Washington) or by a site's institutional ethics/

were reviewed.

review board when a local IRB maintained jurisdiction.

At enrollment, investigators documented demography, medical and

The safety endpoint was assessed by documenting and analysis

surgical history, and performed a physical examination—including awake

of all adverse events (AEs) that occurred during the trial. The primary

fiberoptic nasopharyngeal, hypopharyngeal endoscopy and oral cavity
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TABLE 2

The S.I.Le.N.C.E inclusion and exclusion criteria

Inclusion criteria
1. Age > 22 years (no maximum age)
2. Has consistent bed/sleep partner willing to provide coparticipant informed consent
3. Has basic computer literacy (eg, email) and home internet access
or smartphone
4. Chronic, simple snoring (bed/sleep partner-verified)
5. No prior surgical treatment for snoring
6. Willing and capable of providing Informed Consent
Exclusion criteria
1. Age < 22 years
2. Has no consistent bed/sleep partner
3. Intermittent or occasional snoring
4. Body mass index >32 kg/m2
5. Friedman tongue position 3 or 4
6. Tonsil Grade 3 or 4
7. Significant nasal obstruction
8. Previous palatal surgery
9. Current cigarette smoker
10. Known history of coronary artery disease or stroke

F I G U R E 1 The Elevo suture implant is provided preloaded into a
specialized suturing needle delivery device

11. Chronic obstructive pulmonary disease
12. Diabetes
13. Major depression or noncontrolled psychiatric illness
14. Drug or alcohol abuse
15. Untreated or poorly controlled hypertension
16. Anticoagulation therapy
17. History of bleeding or clotting disorder
18. Epworth Sleepiness Score > 10, indicative of obstructive sleep
apnea

were inserted into the soft palate under topical and local infiltration
anesthesia. The bidirectional, self-anchoring suture configuration
incorporates tiny barbs spaced evenly in a helical array on either side of
a nonbarbed midsegment. Developed originally used for soft-tissue
approximation to produce lift in facelift procedures,21,22 the barb
configuration and the implant length were optimized for the present
study to provide tissue apposition in the soft palate. The net result is
stiffening and shortening of the soft palate without the need for surgical knots or swaged needles. Each implant was provided preloaded into

examinations to rule out any pathology and to identify Friedman tongue

a specialized suturing needle delivery device (Figure 1).

position (FTP) and tonsil size. Finally, each subject was provided with

The entry points for these implants are approximately 2 to 3 mm

and trained to use a home sleep test (HST) device. The HST device was

distal (posterior) to the hard/soft palate junction. Applying gentle pres-

sent home with the understanding that the subject would self-conduct

sure on the handle, the tip delivery needle was advanced in a gentle

a two-night HST and return the device for data analysis. This HST func-

arch motion through the levator palatine muscles toward the posterior

tioned to confirm the presence of chronic, disruptive snoring and rule

end of the soft palate (the uvula). Some investigators found it helpful to

out moderate/severe OSA (apnea/hypopnea index >15). Following con-

create three initial or “pilot” holes before deploying the Elevo implants,

firmation of both snoring and negative OSA status, the subject and

to ease insertion. A depth insertion marker located on the needle shaft

bed/sleep partner received individual e-mails inviting them to complete

was used for visual reference. As a general rule, the tip was advanced

online baseline questionnaires. The bed/sleep partner rated the sub-

25 to 30 mm distally through the soft palate to an area approximately

ject's snoring severity (via 0-10 VAS). The subject assessed daytime

8 to 10 mm from the distal edge of the soft palate (Figure 2). When

somnolence via the Epworth Sleepiness Index (ESS) and sleep quality

insertion depth was deemed acceptable, a reversal of the arced motion

via the Pittsburgh Sleep Quality Index (PSQI). In addition, the subject

of the handle uncoupled the implant and enabled the needle to be with-

was scheduled for the Elevoplasty procedure.

drawn, leaving the implant in place with both sets of barbs engaged in
tissue and the tension suture protruding out of the subject's palate and
mouth. This process was repeated for the each of the implants.

2.3

|

Elevoplasty procedure

The three implants were deployed within the width of the subject's
soft palate. One implant was inserted along the subject's midline. The

Each subject was treated with an in-office Elevoplasty procedure

remaining two implants were generally inserted approximately 5 to

whereby three, fully resorbable (polydioxanone), barbed suture implants

10 mm laterally on each side and advanced in a slight radiating pattern
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On the following day, subjects were contacted via telephone/text
message to query postprocedure complications, pain, and pain medication usage. Subjects were scheduled to return in 1 month (or earlier
if necessary) for a standard postprocedure follow-up.

2.4

|

Data collection

Prior to the procedure, each subject and bed/sleep partner were
trained on the use of an online outcomes-tracking database (Trials.ai,
San Diego, California). Online questionnaire assessments were
prompted by e-mails to both the subject and the bed/sleep partner at
the following four intervals: (a) before the procedure (baseline),
(b) 30 days after the procedure, (c) 90 days after the procedure, and
F I G U R E 2 Gentle pressure is applied on the handle as the tip of
the needle is advanced in an arched motion through the uvular and
levetor palatine muscles of the soft palate

(d) 180 days after the procedure. Assessments included ESS and
PSQI for the subjects and a VAS 0 to 10 score assessment of the
study subject's snoring severity entered by the bed/sleep partner.
In addition, each subject was provided with an HST device (SNAP
Diagnostics, LLC, Wheeling, IL, Model 8) at each interval for two-night
sleep studies. This device uses sound energy measurements and oximetry to screen for OSA.23,24 HST testing provided detailed, acoustical
analysis of snoring by quantifying snoring index (snore events/hour),
average snoring loudness, maximal snoring loudness, and average snoring frequency.25 The HST recordings (minimum 4 hours recording) were
analyzed independently. The snoring events were classified into five
predefined types: (a) type I: mostly palatal; (b) type II: mostly palatal +
tongue; (c) type III: sound, but no particular pattern, can originate in
lungs, or upper airway; (d) type IV: high pitch, more diffuse, similar to
asthma; and (e) type WL: wheezing-like. As derivatives of these outcome measures, noise ratios were calculated using the algorithms below
to compute the percentage of snoring believed to be of palatal origin
(measure #1) and ratio of loudness of palatal snoring vs background
noise (measure #2).
1. Measure #1: percent (%) of snoring events comprised of types (I + II)/
(I + II + III + IV + WL); and
2. Measure #2: average loudness ratio of events: (loudest 15% of type
I and II)/(average loudness nonsnoring breathing events loudness) on
Base 10 log.

F I G U R E 3 Gently traction on the silk sutures causes mild tissue
apposition (“accordion-ing”) and results in elevaton, shorten, and
stiffen the soft palate. The proximal barbs engage with tissue to
maintain the tension

Since inclusion criteria did not restrict enrollment to patients with
a predominance of a specific snoring type, the study assessed the preand post-treatment measures to detect a change in palatal snoring vs
other breathing sounds. In total, the endpoints the trial consisted of

so that the tip of the suture implant resides approximately 10 to 15 mm

1 primary endpoint and 14 secondary endpoints (Table 1).

lateral to the distal end of the fully advanced middle suture implant.
Once all implants were placed, the black silk sutures protruding from
the subject's palate were each manually retracted causing a mild tissue

2.5

|

Statistical analysis

apposition (“accordion-ing”) of the soft palate tissue (Figure 3). This
action was meant to slightly raise, shorten, and stiffen the soft palate,

Sample size was selected based on the potential of the lower bound of

with the proximal barb row engaging with tissue to gently ratchet ten-

a two-sided 95% confidence interval to exceed 50%, if the patient

sion. After an approximately 1 to 4 mm of soft palate lift was achieved,

selection criteria were appropriate. Given that no p redetermined

the silk sutures were cut and withdrawn.

multiple comparison rule was defined a priori, all probability values
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provided are nominal. Continuous variables are presented as mean ± SD

Safety outcomes from the trial indicate low risk of harm to patients.

and categorical variable data as frequencies and percentages. Multiple

There were no reported adverse events. Two subjects reported being

paired t-tests were used to assess statistical differences between mea-

able to palpate an implant with their tongues after discharge. In both

sures collected at baseline and compared to 30-day, 90-day, and

those cases, an extruding section of the implant was discovered and

180-days postprocedure. Probability values <.05 are considered statisti-

treated with a simple trimming of the protruding portion of the implant

cally significant. All statistical analyses were conducted in SAS version

in a brief follow-up office visit. This trimming with scissors involved no

9.3 (SAS Institute, Cary, North Carolina).

anesthesia, bleeding, or pain.
All subjects were contacted on the evening of postprocedure day
1 to elicit peak pain VAS on both the evening of procedure and on

3

|

RESULTS

postprocedure day 1. Peak postprocedure pain VAS, collected on the
evening of the procedure was as reported on a 0 to 10 VAS was 3.85

Fifty-two study subjects were treated across seven of the eight cen-

± 2.69 and. 24 hours later (postprocedure day 1) was 2.90 ± 2.21.

ters that gained IRB approval to enroll subjects. Enrollment included

Only 3 out of 52 (5.8%) reported using an opioid for postprocedure

33 males, 19 females, and their bed/sleep partners.

pain control on the evening of or day after the procedure.

Prior to treatment (baseline), the subject's mean VAS score for
snoring severity as assessed by the bed/sleep partner was 7.81 ± 1.59.
At 30-days postprocedure, the VAS score (Primary Endpoint) decreased

4

|

DI SCU SSION

significantly to 5.77 ± 2.35 (t(51) = 6.390, P < .001). At 90-days
postprocedure, the snoring severity mean VAS score (Secondary End-

The present study was conducted in selected adult patients suffering

point #1) was 4.48 ± 1.81 (t(47) = 7.141, P < .001). The 180-days mean

from chronic, disruptive snoring based on their bed/sleep partner

VAS score (Secondary Endpoint #10) was 5.40 ± 2.28 (t(44) = 7.097,

reporting, the subject's own assessment of sleep quality and confirmed

P < .001). The mean within-subject ESS (0-24) at baseline was 6.63

by HST snoring sound recordings. Snoring is often linked to OSA and

± 4.00 and decreased to 5.38 + 3.21 (P < .05) at 30 days postprocedure.

admittedly, the anatomic causes of snoring may also contribute to the

This decrease in ESS was sustained at 90-days (5.06 ± 3.03 [P < .01])

OSA syndrome. However, the airway obstruction in OSA is often multi-

and 180-days postprocedure (4.63 ± 2.54 [P < .01]), These results com-

level in origin. Since the focus of this study dealt with treatment of

prise the prospectively-defined secondary endpoints #7, #9, and #12.

snoring at the level of the soft palate, patients with coexisting moderate

The trial results also achieved significance in the mean within-

to severe OSA were specifically excluded to more clearly discern any

subject change in subject-reported PSQI results. The mean PSQI score

improvement in sleep quality without the background of OSA. The

(0-21) at baseline was 7.04 ± 3.53. The mean PSQI score at 30-days

objectives of the other inclusion and exclusion criteria (Table 2) were

postprocedure had decreased to 5.51 ± 2.58 (P < .001). This decreased

similarly aimed to recruit those patients who could potentially most

persisted through 180-days; at 90-days 5.47 ± 2.76 (P < .001) and at

benefit from palatal stiffening and in whom demonstrable clinical

180-days postprocedure 5.51 ± 2.99 (P < .001). These results comprise

improvement might be clearly recognizable.17,26

the prospectively-defined secondary endpoints #6, #8, and #11.

The results of the multi-institutional trial demonstrated a statisti-

Table 3 displays comparative data collected from the two

cally significant and prolonged decrease in mean snoring severity VAS

prospectively-defined HST snoring noise ratio measurement (second-

as assessed by the bed/sleep partner and thus, confirmed the

ary endpoints #2, #3, #4, #5, #13, and #14). The trial results achieved

prospectively-defined primary and several secondary endpoints. The

some numerical improvement, but not statistical significance in either

mean decrease at the 30-day interval was 25% and decreasing further

percentage of snoring event types (HST measure #1) or average event

still to an approximately 30% at 90- and 180-days post treatment. In

loudness ratio (HST measure #2).

addition, significant and prolonged improvements in subject-reported

TABLE 3

Data summary of primary and secondary study outcome measures
Baseline

30-Day (n = 52)

90-Day (n = 48)

180-Day (n = 45)

Snoring VAS 1 and 2 endpoints
#1 and #10

7.81 ± 1.59

ESS 2 endpoints #7, #9, and #12

6.63 ± 4.00

5.38 + 3.21 (P < .5)

5.06 + 3.03 (P < .1)

4.63 + 2.54 (P < .1)

PSQI 2 endpoints #6, #8, and #11

7.04 ± 3.53

5.51 ± 2.58 (P < .001)

5.47 ± 2.76 (P < .001)

5.51 ± 2.99 (P < .001)

HST measure #1 (%) 2 endpoints
#2, #4, and #13

11.75 ± 8.93

12.23 ± 8.94 (NS)

12.00 ± 12.21 (NS)

10.19 ± 10.59 (NS)

HST measure #2 (dB) 2 endpoints
#3, #5, and #14

18.50 ± 7.08

19.90 ± 6.90 (NS)

19.54 ± 9.98 (NS)

17.24 ± 8.78 (NS)

5.77 ± 2.35 (P < .001)

4.48 ± 1.81 (P < .001)

5.40 ± 2.28 (P < .001)

Note: Data presented as mean ± SD. Statistical significance accepted when P < .05.
Abbreviations: dB, Decibels; ESS, Epworth Sleepiness Scale; HST, home sleep testing; NS, not significant; PSQI, Pittsburgh Sleep Quality Index;
VAS, snoring severity visual analogue scale as recorded by bed/sleep partner.
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sleep quality and daytime alertness represented an additional six sec-

extruded segment. There were no complete extrusions. In addition,

ondary endpoints. It must be noted that although the primary and 8 of

postprocedure pain was very minor in level and short in duration. No pain

14 secondary endpoints were achieved, all these were subjective end-

medication usage was specifically directed at postprocedure pain was

points. The remaining six secondary endpoints were based on SNAP

reported after postprocedure day 1.

Diagnostics sound adjudication algorithms for HST sound recordings of
snoring. Statistical analysis found no improvement in the two calculated measures involving snoring type analysis or snoring volume analy-

5

|

CONC LU SIONS

sis (Table 3). However, since the inclusion criteria did not limit
enrollment to only those with snoring believed to be of palatal origin,

Based on the results of the current study, we believe that this mini-

the cohort included patients exhibiting little or no palatal (type

mally invasive office procedure can be a safe tool in treating patients

1 or type II) snoring and thus, changes in HST measures #1 and HST

suffering from predominantly palatal snoring. The limited data on our

measures #2 might have been minimized.

selected group of patients indicates a moderate reduction in snoring.

This study was designed to establish the effectiveness of the
Elevo implant and the Elevoplasty procedure in a population of non-

CONFLIC T OF INT ER E ST

OSA snoring patients and not just among a subset of patients with

Dr Friedman is a member of the Zelegent, Inc. advisory panel and is a

predominantly palatal snoring. Had HST measures #1 and #2 been

(0.075%) shareholder of Zelegent, Inc. Dr Gillespie is a member of the

used as inclusion criteria, we might have increased the magnitude of

Zelegent, Inc. advisory panel and is a recipient of a grant (or funding)

our efficacy indices. However, this also might have limited the applica-

from Zelegent, Inc. Dr Meyer is a recipient of a grant (or funding) from

bility of the procedure to those prescreened for palatal snoring.
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